This article, written by Meg Egan Auderset at Clarivate Analytics, describes how the new draft industry guidance from the US Food and Drug Administration (FDA) …
A number of trends (both in science and on the regulatory front) bode well for the development and availability of drugs to treat rare diseases. …
The Russian MoH approved 158 new clinical trials of all types including local and bioequivalence studies during Q3 2017, demonstrating a 34% decrease in comparison …
The key aim of the new EU Clinical Trial Regulation, which is currently planned for implementation in mid-2019, is to boost clinical research in the …
The age of paediatric melanoma used to be a theoretical discussion, but has become a real-life challenge due to arbitrary age limits decreed by regulatory …
There has been a renewed interest in clinical trials of drugs to treat early Alzheimer’s disease, owing partially to recent advances in the understanding of pathophysiological …
The Australian clinical trials landscape has developed considerably over recent years with over 1000 new clinical trials commencing each year in the pharmaceutical, biotechnology and …
Following on from the last article featured by Svetlana Zavidova from the Association of Clinical Trials Organizations (ACTO) in the July 2017 JCS on clinical …
Clinical research is a rapidly evolving and dynamic environment and the sector is undergoing significant changes on a number of fronts. The wider use of …
Conducting a clinical trial is a huge and complex undertaking, and there are, more often than not, challenges. And in an undertaking as scientifically and …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
